Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12626001367336
Ethics application status
Approved
Date submitted
24/09/2026
Date registered
16/11/2026
Date last updated
16/11/2026
Date data sharing statement initially provided
16/11/2026
Type of registration
Retrospectively registered
Titles & IDs
Public title
An observational study comparing the autonomic nervous system and blood markers in people with heart symptoms but no major coronary artery blockages, people with coronary artery blockages, and healthy volunteers
Query!
Scientific title
A longitudinal observational study characterising a distinct profile of autonomic function and circulating blood biomarkers in adults with non-obstructive coronary artery disease compared with adults with obstructive atherosclerotic coronary artery disease and healthy controls
Query!
Additional trial identifiers [1]
318499
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
INFO-NOCA (Novel INfluential Factors in the natural histOry of Non-Obstructive Coronary Artery diseases)
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Myocardial Infarction
343689
0
Query!
Spontaneous Coronary Artery Dissection
343690
0
Query!
Vasospastic Angina
343691
0
Query!
Atherosclerotic coronary artery disease
343692
0
Query!
Postural Orthostatic Tachycardia Syndrome
343693
0
Query!
Systemic inflammatory conditions
343694
0
Query!
Autonomic Dysfunction
343702
0
Query!
Endothelial Dysfunction
343703
0
Query!
Condition category
Condition code
Cardiovascular
339811
339811
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
339812
339812
0
0
Query!
Other cardiovascular diseases
Query!
Neurological
339819
339819
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
True
Query!
Target follow-up duration
5
Query!
Target follow-up type
Years
Query!
Description of the intervention or exposure
Group 1: Participants with acute myocardial infarction caused by coronary atherosclerosis
Group 2: Participants recently diagnosed with spontaneous coronary artery dissection (SCAD)
Group 3: Participants diagnosed with vasospastic angina (VSA)
Group 4: Participants with a prior SCAD diagnosis (more than one year ago)
Group 5: Healthy control participants
The following section provides a brief summary of the study procedures that participants will undergo during each visit.
Baseline / Enrolment (In-person)
Applicable to all participants
• Study overview provided and written informed consent obtained
• Collection of clinical and imaging data (e.g., Invasive angiographic data, Computed tomography coronary angiography (CTCA) and CT angiography head to pelvis, Echocardiograms, Cardiac Magnetic Resonance Imaging (MRI))
• Collection of 50 mL fasting blood sample for exploratory analysis
Only Group 3, 4, and 5 participants will undergo:
• Measurement of vital signs (blood pressure, temperature, heart rate, height and weight) and pupillary light reflex
• Full autonomic and vascular/endothelial function testing (see detailed protocol below)
• Completion of self-reported questionnaires
• Collection of routine blood testing results
• 24-hour Holter monitoring and ambulatory BP measurement
Visit 2: 3 months ± 4 weeks (In-person)
Applicable to Group 1 and 2 participants only
• Review of current medications and recovery status
• Measurement of vital signs and pupillary light reflex
• Completion of self-report questionnaires
• Full autonomic and endothelial function testing
• Collection of routine blood testing results
• Collection of 50 mL fasting blood sample for exploratory analysis
• 24-hour Holter monitoring and ambulatory BP measurement
Visit 3: 12 months ± 4 weeks (In-person)
Applicable to Group 1, 2 and 3 participants only
• Review of medical history and current medications
• Collection of any new clinical data since the previous visit
• Measurement of vital signs and pupillary light reflex.
• Completion of self-report questionnaires
• Collection of routine blood testing results
• Collection of 50 mL fasting blood sample for exploratory analysis
• Shortened autonomic function testing protocol
• 24-hour Holter monitoring and ambulatory BP measurement
Visit 4: Three years post-enrolment
Applicable to Group 1, 2, 3 and 4 participants
• Review of clinical events post-last contact
• Review of medications
• Groups 1 and 2 only: Completion of a short survey for symptom burden and QoL assessment
Visit 5: Five years post-enrolment
Applicable to Group 1, 2, 3 and 4 participants
• Review of clinical events post-last contact
• Review of medications
• Groups 1 and 2 only: Completion of a short survey for symptom burden and QoL assessment
Query!
Intervention code [1]
335412
0
Not applicable
Query!
Description of the comparator or control
• Group 5: Healthy Control (Baseline visit only)
Healthy volunteers with no history of cardiovascular, renal, respiratory, neurological, or systemic inflammatory conditions. Control participants will be recruited via university networks, community advertisements, and outpatient flyers.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
346987
0
(This is the composite primary outcome) The proportion of participants with moderate to severe autonomic dysfunction, measured by Composite Autonomic Scoring Scale (CASS) score of 4 to 10, in patients with NOCA compared with obstructive coronary artery disease and healthy controls at baseline.
Query!
Assessment method [1]
346987
0
Each of the autonomic testing component will contribute to the total Composite Autonomic Scoring Scale (CASS) which is the sum of the scores from sudomotor (0-3 points), cardiovagal (0-3 points), and adrenergic (0-4 points) testing, with a maximum score of 10 indicating severe autonomic dysfunction: Sudomotor function (~5 minutes): Assessed using the SUDOSCAN® device to evaluate small-fibre sympathetic function via sweat gland activity. Using non-invasive, continuous beat-to-beat hemodynamic monitor Finapres NOVA to measure: Cardiovagal (parasympathetic) function (~20 minutes): Measured through heart rate variability in response to deep breathing and the Valsalva manoeuvre. Adrenergic (sympathetic) function (~15 minutes): Evaluated via blood pressure responses during the 10-minute active stand test and baroreflex function during the Valsalva manoeuvre, and the cold pressor test, which measures sympathetic reactivity and vascular response to cold-induced stress.
Query!
Timepoint [1]
346987
0
Baseline
Query!
Secondary outcome [1]
468491
0
(Note: This should be a composite outcome, as Group 1,2, and 3will be compared between each other over the 12-month follow-up and evaluated its changes with the association in persisted symptoms.) Changes in quality of life over a 12-month follow-up in Groups 1, 2 and 3 associated with persistence of symptoms
Query!
Assessment method [1]
468491
0
Using validated questionnaires as a composite assessment for this secondary outcome EuroQol 5-Dimension 5-Level Questionnaire, Anxiety Sensitivity Index-3, Seattle Angina Questionnaire-7, Centre for Epidemiological Studies - Depression, Composite Autonomic Symptom Score-31, Malmö POTS Score
Query!
Timepoint [1]
468491
0
12-month follow-up Note: This full set of questionnaires is administered only at baseline and at the 12-month follow-up.)
Query!
Secondary outcome [2]
468950
0
Changes in autonomic-endothelial interlinked function over a 12-month follow-up in Groups 1, 2 and 3.
Query!
Assessment method [2]
468950
0
The autonomic function testing protocol comprehensively evaluates: • Vital signs and pupillometry (~15 minutes): Measured temperature (Digital non-contact thermometer), height (wall-mounted height measure) and weight (digital scale), waist circumference, blood pressure and heart rate (Omron blood pressure monitor) , cardiac electrical signal (12-lead ECG) and pupil reflexes to light (NPi pupillometer). Composite analysis of autonomic function will use results from these tests: • Sudomotor function (~5 minutes): Assessed using the SUDOSCAN® device to evaluate small-fibre sympathetic function via sweat gland activity. • Cardiovagal (parasympathetic) function (~20 minutes): Measured through heart rate variability in response to deep breathing and the Valsalva manoeuvre. • Adrenergic (sympathetic) function (~15 minutes): Evaluated via blood pressure responses during the 10-minute active stand test and baroreflex function during the Valsalva manoeuvre, and the cold pressor test, which measures sympathetic reactivity and vascular response to cold-induced stress. • 24-hour circadian modulation: Monitored using continuous ECG and ambulatory BP to assess day–night autonomic fluctuations, heart rate variability, and blood pressure variability. The endothelial and vascular function assesed by these measures • Flow-Mediated Dilation (FMD) (~30 minutes): Measures endothelium-dependent vasodilation of the brachial artery in response to reactive hyperaemia using high-resolution ultrasound and automated diameter tracking software. • Pulse Wave Analysis (PWA) and Pulse Wave Velocity (PWV) (~10 minutes): Assesses arterial stiffness and wave reflection by recording peripheral arterial waveforms and calculating pulse wave transit time between carotid and femoral arteries. • Strain-Gauge Plethysmography (SGP) (~15 minutes): Evaluates baroreflex-mediated vascular adaptation by measuring forearm vascular resistance during an orthostatic challenge.
Query!
Timepoint [2]
468950
0
Baseline and 12 months
Query!
Secondary outcome [3]
469852
0
Occurrence of a composite cardiovascular outcome comprising myocardial infarction, recurrent spontaneous coronary artery dissection (SCAD), unplanned coronary revascularisation, and cardiovascular-related hospitalisation, assessed through participant follow-up and review of available medical records.
Query!
Assessment method [3]
469852
0
Participant-reported cardiovascular events, verified through available medical records.
Query!
Timepoint [3]
469852
0
3- and 5-year follow-up
Query!
Eligibility
Key inclusion criteria
• Adults aged 18 to 65 years; and
• Patients who have experienced acute myocardial infarction due to coronary atherosclerosis (Group 1); OR
• Patients who have undergone clinically indicated invasive coronary angiography for acute myocardial infarction due to spontaneous coronary artery dissection (Group 2), OR
• Patients with angina confirmed to be due to vasospastic angina (Group 3), OR
• Patients with a confirmed diagnosis of spontaneous coronary artery dissection more than one year prior (Group 4); OR
• Healthy individuals without history of cardiovascular, renal, respiratory, liver, neurological, or systemic inflammatory conditions (Group 5). OR
* Patients with a confirmed diagnosis of Postural Orthostatic Tachycardia Syndrome (Group 6);
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
Yes
Query!
Key exclusion criteria
• Inability to provide informed consent
• Inability to safely withhold rate-limiting/prescribed medications for autonomic testing
• Terminal illness, precluding completion of 12 months of follow-up
• Cognitive or physical impairments limiting cooperation, or inability to complete autonomic function testing
• Recent major surgery
• Inability or unwillingness to attend follow-up visits at 3- and 12- months (Groups 1 and 2) or at 12- months (Group 3) for Multiple-Visit Groups participants to conduct autonomic function testing and blood collection
• History of haemorrhagic stroke
• Poorly controlled hypertension (blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 95 mmHg diastolic)
• Left ventricular ejection fraction <40%
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Both
Query!
Statistical methods / analysis
The data collected will be de-identified and analysed using a range of descriptive, comparative, and multivariable methods to address the study’s aims and test the central hypothesis. Initial analyses will involve descriptive statistics to summarise demographic, clinical characteristics, autonomic nervous system (ANS) and vascular function, and patient-reported outcomes across the defined participant groups. Continuous variables (e.g., heart rate varibility - HRV, % flow-mediated dilation) will be presented as mean ± standard deviation or median with interquartile ranges depending on data distribution, while categorical variables (e.g., sex, comorbidity presence) will be summarised as frequencies and percentages.
Comparisons between study-specific groups will be conducted to assess differences in autonomic function, endothelial and vascular health, inflammatory biomarkers, symptom burden, and quality of life (QoL). One-way ANOVA or Kruskal-Wallis tests will be applied depending on data type with multiple comparison corrections where appropriate. Categorical variables will be compared using Chi-square or Fisher’s exact tests.
To assess longitudinal changes over time within subjects, repeated measures analyses will be performed using linear mixed-effects models for continuous outcomes and generalised estimating equations for categorical data.
Correlational analyses will explore whether associations between autonomic dysfunction, inflammation, and endothelial impairment are interrelated and contribute to symptoms and prognosis in NOCA disease. Pearson or Spearman correlation will be used as appropriate, supplemented by multivariable linear or logistic regression to assess independent relationships between predictors (e.g., CASS score, HRV) and outcomes such as QoL, anxiety, depression, and symptom persistence. In addition, stratified analyses will be conducted to determine whether the relationship between ANS dysfunction and outcomes differs by sex.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/08/2026
Query!
Date of last participant enrolment
Anticipated
31/12/2030
Query!
Actual
Query!
Date of last data collection
Anticipated
31/01/2036
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
30269
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
30270
0
The Queen Elizabeth Hospital - Woodville
Query!
Recruitment postcode(s) [1]
46671
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
46672
0
5011 - Woodville
Query!
Funding & Sponsors
Funding source category [1]
323076
0
University
Query!
Name [1]
323076
0
Adelaide University Research Cost Centre
Query!
Address [1]
323076
0
Query!
Country [1]
323076
0
Australia
Query!
Funding source category [2]
323098
0
University
Query!
Name [2]
323098
0
Adelaide University Clinical Trial Facility
Query!
Address [2]
323098
0
Query!
Country [2]
323098
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
South Australian Health and Medical Research Institute
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
326049
0
University
Query!
Name [1]
326049
0
Adelaide University
Query!
Address [1]
326049
0
Query!
Country [1]
326049
0
Australia
Query!
Other collaborator category [1]
284131
0
Individual
Query!
Name [1]
284131
0
In-kind support from CI Professor Peter Psaltis - Vascular Research Centre
Query!
Address [1]
284131
0
Query!
Country [1]
284131
0
Australia
Query!
Other collaborator category [2]
284132
0
Individual
Query!
Name [2]
284132
0
In-kind support from Dr Jessica Marathe - Royal Adelaide Hospital - Cardiology
Query!
Address [2]
284132
0
Query!
Country [2]
284132
0
Australia
Query!
Other collaborator category [3]
284133
0
Individual
Query!
Name [3]
284133
0
In-kind support from Dr Marie-Claire Seeley - Adelaide University
Query!
Address [3]
284133
0
Query!
Country [3]
284133
0
Australia
Query!
Other collaborator category [4]
284134
0
Individual
Query!
Name [4]
284134
0
In-kind support from Ms Dang Xuan Anh Tran - Adelaide University
Query!
Address [4]
284134
0
Query!
Country [4]
284134
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
321477
0
Central Adelaide Local Health Network HREC
Query!
Ethics committee address [1]
321477
0
https://www.rah.sa.gov.au/research/for-researchers/central-adelaide-local-health-network-human-research-ethics-committee
Query!
Ethics committee country [1]
321477
0
Australia
Query!
Date submitted for ethics approval [1]
321477
0
04/12/2025
Query!
Approval date [1]
321477
0
16/06/2026
Query!
Ethics approval number [1]
321477
0
223334
Query!
Summary
Brief summary
INFO-NOCA study aims to advance understanding of heart artery conditions that can cause heart attack–like symptoms, and even heart attacks, in the absence of cholesterol-related blockages, the most common cause of coronary events. Collectively referred to as non-obstructive coronary artery (NOCA) diseases, these conditions remain poorly understood and are often under-recognised in clinical practice. By integrating detailed clinical data, non-invasive assessments of autonomic (nerve) and vascular function, and analysis of novel blood-based biomarkers, this project seeks to uncover the biological mechanisms underlying persistent symptoms and disease progression. The study will also establish a comprehensive biobank and identify potential biomarkers to support more personalised approaches to diagnosis and management in the future. This research is conducted by a collaborative team at the South Australian Health and Medical Research Institute (SAHMRI), the Adelaide University, the Royal Adelaide Hospital (RAH), and The Queen Elizabeth Hospital (QEH), led by Principal Investigator Professor Peter Psaltis, an Interventional Cardiologist. Recruitment will occur through the RAH and QEH, with study procedures undertaken at SAHMRI and the Adelaide University Clinical Trials Laboratory at the Bonython Jubilee Building on Frome Road.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
153842
0
Prof Peter Psaltis
Query!
Address
153842
0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Query!
Country
153842
0
Australia
Query!
Phone
153842
0
+61 432 359 686
Query!
Fax
153842
0
Query!
Email
153842
0
[email protected]
Query!
Contact person for public queries
Name
153843
0
Dang Xuan Anh Tran
Query!
Address
153843
0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Query!
Country
153843
0
Australia
Query!
Phone
153843
0
+61 8 8128 4213
Query!
Fax
153843
0
Query!
Email
153843
0
[email protected]
Query!
Contact person for scientific queries
Name
153844
0
Dang Xuan Anh Tran
Query!
Address
153844
0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Query!
Country
153844
0
Australia
Query!
Phone
153844
0
+61 8 8128 4213
Query!
Fax
153844
0
Query!
Email
153844
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
•
Researchers
Conditions for requesting access:
•
Yes, conditions apply:
•
Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
•
Requires approval by an ethics committee
What individual participant data might be shared?
•
De-identified individual participant data:
•
Published results
What types of analyses could be done with individual participant data?
•
Systematic reviews and meta-analyses
•
Studies exploring new research questions
•
Health economic analyses
•
Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
•
Email of trial custodian, sponsor or committee:
On request to the Principal Investigator (Prof Peter Psaltis,
[email protected]
OR
[email protected]
), released as de-identified data under an institutional data-sharing/transfer agreement and subject to ethics approval
Are there extra considerations when requesting access to individual participant data?
Yes:
Require institutional data-sharing/transfer agreement and subject to ethics approval
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF